Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
Animals
Hydrogen Peroxide
Macaca mulatta
Vaccines, Inactivated
/ immunology
Yellow Fever Vaccine
/ immunology
Yellow Fever
/ prevention & control
Yellow fever virus
/ immunology
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Disease Models, Animal
Vaccines, Attenuated
/ immunology
Chlorocebus aethiops
Vero Cells
Humans
LNI
NT(50)
correlate of protection
flaviviruses
immunological memory
neutralizing antibodies
rhesus macaques
vaccination
yellow fever
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
13
11
2023
revised:
06
03
2024
accepted:
19
06
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
17
7
2024
Statut:
ppublish
Résumé
Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT
Identifiants
pubmed: 39019010
pii: S2666-3791(24)00369-0
doi: 10.1016/j.xcrm.2024.101655
pii:
doi:
Substances chimiques
Hydrogen Peroxide
BBX060AN9V
Vaccines, Inactivated
0
Yellow Fever Vaccine
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101655Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests Oregon Health & Science University (OHSU), M.K.S., E.H., and I.J.A. have a financial interest in Najít Technologies, Inc., a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU and Najít Technologies, Inc. M.S.D. is a consultant or member of a scientific advisory board for InBios, Ocugen, Vir Biotechnology, Topspin Therapeutics, and Moderna. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Emergent BioSolutions, Moderna, and Vir Biotechnology. I.J.A. and E.A.P. are inventors on US patent no. 10,744,198 entitled “Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production” and US patent nos. 11,141,475 and 11,633,470 entitled “Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process.” M.K.S. and E.H. are inventors on US patent nos. 8,124,397 and 8,716,000 entitled “Inactivating pathogens with oxidizing agents for vaccine production.” No writing assistance was utilized in the production of this manuscript.